Get the Stockscreener App
49.12
3.31%
-1.68
Structure Therapeutics Inc Adr stock is traded at $49.12, with a volume of 655.41K.
It is down -3.31% in the last 24 hours and up +1.99% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
See More
Previous Close:
$50.80
Open:
$50.76
24h Volume:
655.41K
Relative Volume:
0.84
Market Cap:
$3.49B
Revenue:
-
Net Income/Loss:
$-170.73M
P/E Ratio:
-18.25
EPS:
-2.6921
Net Cash Flow:
$-159.70M
1W Performance:
+1.32%
1M Performance:
+1.99%
6M Performance:
-45.65%
1Y Performance:
+168.86%
1-Day Range:
$49.04
$51.00
1-Week Range:
$46.06
$52.60
52-Week Range:
$15.80
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(650) 457-1978
Address
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
49.12 | 3.49B | 0 | -170.73M | -159.70M | -2.6921 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Canaccord Genuity | Buy |
| Mar-26-26 | Initiated | Wolfe Research | Peer Perform |
| May-02-25 | Initiated | Citigroup | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Dec-04-24 | Initiated | H.C. Wainwright | Buy |
| Sep-23-24 | Initiated | Morgan Stanley | Overweight |
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
A small-cap contender looking to challenge the weight-loss drug giants | 2026-07-24 | Investing News - Stockhouse
Form 4 Structure Therapeutics Inc ADR For: 24 July By Investing.com - Investing.com Nigeria
FMR LLC Discloses Major Beneficial Ownership Changes in Structure Therapeutics Inc. - Kalkine Media
FMR LLC funds sell 17,452 Structure Therapeutics (GPCR) ADS at $50.07 - Stock Titan
GPCR: Structure Therapeutics IncADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q2 Results? - TradingView
Analysts Are Bullish on These Healthcare Stocks: Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Does EU Approval of Wegovy Pill Change NVO's Competitive Story? - TradingView
(GPCR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Takeover Buzz Sends Structure Therapeutics Soaring - TipRanks
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Fractyl Health, Inc. (GUTS) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Merck & Company (MRK) and Viking Therapeutics (VKTX) - The Globe and Mail
Structure Therapeutics Slumps As Obesity Hype Cools - TipRanks
Form 4 Structure Therapeutics Inc ADR For: 15 July By Investing.com - Investing.com Nigeria
Structure Therapeutics (NASDAQ: GPCR) CSO exercises options and sells ADS - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), GE Healthcare Technologies Inc (GEHC) - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Sanofi (SNY) and Johnson & Johnson (JNJ) - The Globe and Mail
NVO Rallies 11% in a Month: How Should Investors Play the Stock? - TradingView
LLY Hits Another Record High: Is the Stock Too Expensive to Buy Now? - TradingView
If You Invested $1,000 in Structure Therapeutics Inc ADR (GPCR) - Stock Titan
GPCRStructure Therapeutics Inc ADR Options - Finviz
Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock? - TradingView
Analysts Offer Insights on Technology Companies: Septerna, Inc. (SEPN) and Strategy (MSTR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL) and Roche Holding AG (OtherRHHVF) - The Globe and Mail
Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters? - TradingView
Form 4 Structure Therapeutics Inc ADR For: 29 June By Investing.com - Investing.com Nigeria
[Form 4] Structure Therapeutics Inc. Insider Trading Activity - Stock Titan
(GPCR) Risk Channels and Responsive Allocation - Stock Traders Daily
Structure Therapeutics, Inc. Sponsored ADR Actuals & Estimates (NASDAQ:GPCR) - TradingView
Form 144 Structure Therapeutics Inc. For: 25 June By Investing.com - Investing.com South Africa
[144] Structure Therapeutics Inc. SEC Filing - Stock Titan
Case Summary: Sangamo Therapeutics Chapter 11 - Bondoro
After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching - AOL.com
Analysts Conflicted on These Healthcare Names: Phreesia (PHR) and Novo Nordisk (NVO) - The Globe and Mail
Shareholders Approve Directors, Auditors at 2026 Meeting - The Globe and Mail
Director at Structure Therapeutics (NASDAQ: GPCR) gets 39,453 options - Stock Titan
Structure Therapeutics (GPCR) director receives 39,453 share options at $15 - Stock Titan
Structure Therapeutics (GPCR) grants 39,453-share option award to director - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) reports 2026 shareholder voting outcomes - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
(GPCR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock? - TradingView
Why Structure Therapeutics’ Hot Obesity Stock Is Suddenly Sinking - TipRanks
Analysts’ Top Healthcare Picks: MBX Biosciences, Inc. (MBX), Kura Oncology (KURA) - The Globe and Mail
H.C. Wainwright cuts Structure Therapeutics stock price target to $70 By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Nuvalent (NUVL) and Viking Therapeutics (VKTX) - The Globe and Mail
Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs? - TradingView
Why Structure Therapeutics Shares Are Suddenly Sinking - TipRanks
Structure Therapeutics Maintained at Buy as Analyst Highlights Best-in-Class Oral GLP-1 Profile and Keeps $145 Price Target Unchanged - TipRanks
3 potential takeover targets in obesity - Pharma Voice
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity - The Manila Times
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):